Intervention
Tenofovir Disoproxil Fumarate
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 13 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownEarly Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyNCT05652478 · 2026-09-24
RECRUITINGTenofovir Disoproxil Fumarate in the Treatment of Parkinson's DiseaseNCT06356662 · 2024-01-23
RECRUITINGPharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in BotswanaNCT04862975 · 2024-01-09
COMPLETEDPK of TAF and TDF for PrEP in Pregnant and Postpartum WomenNCT04937881 · 2022-06-13
COMPLETEDModifiers of Tenofovir in the Female Genital TractNCT03377608 · 2017-11-17
COMPLETEDA Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsNCT03537404 · 2017-04-24
COMPLETEDDose Optimisation of Stavudine for the Treatment of HIV InfectionNCT02670772 · 2012-07-01
COMPLETEDExamining Hair to Determine Tenofovir ExposureNCT00903084 · 2009-06-01
COMPLETEDMetabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male VolunteersNCT00648817 · 2006-07-01
COMPLETEDEffectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected AdultsNCT00119379 · 2005-04-01
COMPLETEDStudy of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIVNCT00122486 · 2004-07-01
COMPLETEDReplicor Compassionate Access ProgramNCT05683548
NO_LONGER_AVAILABLEStudy of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIVNCT00122512
TERMINATEDCommon conditions
HIV Infections5Hiv2Acquired Immune Deficiency Syndrome1Ascites Hepatic1Breastmilk Fed Infants of Mothers on Select DOI1Cirrhosis, Liver1Contraception1Decompensated Cirrhosis1Healthy1Healthy Volunteer1Hepatocellular Carcinoma1HIV/AIDS1Human Immunodeficiency Virus1Integrase Strand Transfer Inhibitors1Lactating Women on Select DOI1Lipodystrophy1Metabolic Diseases1Metabolic Effects1Nutrition Disorders1Parkinson Disease1Varices, Esophageal1Viral Hepatitis B1Viral Hepatitis D1Weight Gain1
Leading sponsors
FHI 360
2
National Institute of Allergy and Infectious Diseases (NIAID)
2
Duke University
1
Gilead Sciences
1
Public Health Foundation Enterprises, Inc.
1
R-Pharm
1
Replicor Inc.
1
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
1
University of California, Los Angeles
1
University of Minnesota
1
Willem Daniel Francois Venter
1
Trial status mix
COMPLETED9
RECRUITING2
NO_LONGER_AVAILABLE1
TERMINATED1
Phase mix
PHASE24
PHASE13
PHASE32
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.